About Contact Us Careers
Sign In

Heparin-induced Thrombocytopenia Market - Top Companies and Manufacturers

  • Report ID: 5848
  • Published Date: May 06, 2024
  • Report Format: PDF, PPT

Companies Dominating the Heparin-induced Thrombocytopenia Landscape

    • Endo International plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PlateletBio
    • AUROMEDICS PHARMA LLC
    • Fresenius Kabi USA
    • Pfizer Inc
    • Caplin Steriles Ltd
    • Hikma Pharmaceuticals PLC
    • Teva Pharmaceuticals Industries Limited
    • NOVARTIS AG
    • Eagle Pharmaceutical Inc
    • WEST WARD INC
Browse Key Market Insights with Data Illustration:

In the News

  • Par Sterile Products, a subsidiary of Endo International plc, began to dispatch argatroban to healthcare providers via the Premier ProRx private label program, an insured reserve for hospitals and health systems.
  • Platelet Bio, a biotechnology company dedicated to the discovery and development of an innovative platform for allogeneic cell therapy based on platelet biology, successfully raised $75.5 million in Series B funding in November 2021. Contributions from new investors, SymBiosis, K2 HealthVentures, and Oxford Finance were also part of this funding round together with the ongoing support provided by existing investors. The company intends to use the proceeds of this financing, which represents groundbreaking treatment for immune thrombocytopenia, an autoimmunity disease, to advance the preclinical development of its flagship program on platelets-like cells. In addition, Platelet Bio intends to further develop its innovative engineered PLC platform and improves its manufacturing capabilities.

Author Credits:  Radhika Pawar


  • Report ID: 5848
  • Published Date: May 06, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of heparin-induced thrombocytopenia was over USD 10 billion.

The market size for heparin-induced thrombocytopenia is projected to cross USD 63 billion by the end of 2036 expanding at a CAGR of 5% during the forecast period i.e., between 2024-2036.

The major players in the market are Pfizer Inc, Caplin Steriles Ltd, Hikma Pharmaceuticals PLC, Teva Pharmaceuticals Industries Limited, NOVARTIS AG, Eagle Pharmaceutical Inc., WEST WARD INC, and others.

In terms of end users, the hospital segment is anticipated to account for the largest market share of 40% during 2024-2036.

The North American heparin-induced thrombocytopenia is poised to hold the highest share of 35% by 2036.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample